How does TCR-T cell therapy exhibit a superior anti-tumor efficacy
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.149209 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Dandan Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University…. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, Science and Technology Program of Hunan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
TCR-engineered T cells have achieved great progress in solid tumor therapy, some of which have been applicated in clinical trials. Deep knowledge about the current progress of TCR-T in tumor therapy would be beneficial to understand the direction. Here, we classify tumor antigens into tumor-associated antigens, tumor-specific antigens, tumor antigens expressed by oncogenic viruses, and tumor antigens caused by abnormal protein modification; Then we detail the TCR-T cell therapy effects targeting those tumor antigens in clinical or preclinical trials, and propose that neoantigen specific TCR-T cell therapy is expected to be a promising approach for solid tumors; Furthermore, we summarize the optimization strategies, such as tumor microenvironment, TCR pairing and affinity, to improve the therapeutic effect of TCR-T. Overall, this review provides inspiration for the antigen selection and therapy strategies of TCR-T in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
- Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. Electronic address: 2…
- Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. Electronic address: w…
Förderung
- Natural Science Foundation of Hunan Province
- Science and Technology Program of Hunan Province
- National Natural Science Foundation of China
- Hunan Provincial Science and Technology Department
Zitieren
APA
Yang, D., Duan, Z., Yuan, P., Ding, C., Dai, X., Chen, G., & Wu, D. (2023). How does TCR-T cell therapy exhibit a superior anti-tumor efficacy. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.149209
Vancouver
Yang D, Duan Z, Yuan P, Ding C, Dai X, Chen G, et al. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.149209
BibTeX
@article{Yang2023,
author = {Yang, Dandan and Duan, Zhihui and Yuan, Ping and Ding, Chengming and Dai, Xiaoming and Chen, Guodong and Wu, Daichao},
title = {How does TCR-T cell therapy exhibit a superior anti-tumor efficacy},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.149209}
}
EUVIMED